Skip to content

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$158.92B-2.6%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$622.06B+50.5%
AbbVie logo
AbbVieABBV
$460.96B+24.7%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$635.27M+79.8%
Regenxbio logo
RegenxbioRGNX
$488.35M+58.6%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$990.06M+8,530%

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Calculated from Immix Biopharma, Inc.’s reported figures.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s enterprise value?
Immix Biopharma, Inc. (IMMX) reported enterprise value of $404.29M in Q1 2026.
How has Immix Biopharma, Inc.'s enterprise value changed year-over-year?
Immix Biopharma, Inc.'s enterprise value increased by 1174.9% year-over-year, from $31.71M to $404.29M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.